



Financial Tear Sheet

Corporate Profile

Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that are designed to selectively target and modulate the activity of specific proteins implicated in various disease states. The Company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus, or HBV.

Primary IR Contact


Jonathan Freve
Chief Financial Officer,
Treasurer and Secretary
Phone: 508-473-5993

Stock Information

SBPH (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$12.96
Change (%)	▲ 0.46 (3.68%)
Volume	6,612
52 Week Low	\$6.31
Market Cap	\$164,553,612
Rolling EPS	-2.44
PE Ratio	0
Shares Outstanding	12,697,038

Data as of 08/22/17 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

SEC Filings

Filing Date	Form
08/18/17	424B5
08/18/17	8-K

08/11/17	SC 13G
08/07/17	4

Recent News & Upcoming Events

07/31/17 - 4:15 p.m. There are currently no events scheduled.
 Spring Bank Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial and Operational Results

07/10/17 - 8:30 a.m.
 Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy®

06/22/17 - 9:00 a.m.
 Spring Bank Pharmaceuticals Prices \$37.5 Million Public Offering of Common Stock